Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Exisulind. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 2/20 | 0.58 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.83 |
| ▸ | MAPT | P10636 | 3/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.83 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.83 |
| ▸ | GLA | P06280 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | EDNRA | P25101 | 1/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.83 |
| ▸ | PPARG | P37231 | 10/20 | 0.65 |
| ▸ | RXRA | P19793 | 4/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | DRD1 | P21728 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exisulind SCHEMBL7634632 | 1.00 | CYP1A2 (0.83) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL7631841 | 0.98 | CYP1A2 (0.83) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL7631837 | 0.98 | CYP1A2 (0.83) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL1651133 | 0.91 | CYP1A2 (1.00) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL25371 | 0.91 | CYP1A2 (1.00) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL4776597 | 0.91 | CYP1A2 (1.00) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL20158513 | 0.91 | CYP1A2 (0.83) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| Exisulind SCHEMBL29395528 | 0.91 | CYP1A2 (1.00) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL7789746 | 0.90 | CYP1A2 (0.82) | CYP1A2MAPTMAPK1TDP1CYP3A4 | |
| SCHEMBL7926147 | 0.90 | CYP1A2 (0.82) | CYP1A2MAPTMAPK1TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | OSI PHARMACEUTICALS, INC. | 2002-08-08 | — | — | US | disclosed |
| US-5643959-A | Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | CELL PATHWAYS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107248-A1 | Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof | VHL, IDH3A, GLI2 | PTGS2 1735/4885PTGS1 1681/4885CYP1A2 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.